Shots:
- The US FDA approved Udenyca Onbody earlier in Dec 2023, as an OBI device to administer Udenyca, a biosimilar of pegfilgrastim. The company has launched Udenyca in the US market for the treatment of patients with non-myeloid malignancies
- Udencya is a leukocyte growth factor indicated to be administered the day after CT to lower the rate of infection caused by febrile neutropenia and increase survival in patients exposed to myelosuppressive doses of radiation
- The Udenyca Onbody is comprised of a five-minute injection time, an indicator, a status light, an auditory signal, and a needle that automatically retracts after the administration
Ref: Coherus Biosciences| Image: Coherus Biosciences| Press Release
Related News:- Samsung Bioepis Reports the Initiation of the P-I Trial Evaluation of SB27 (biosimilar, pembrolizumab) for the Treatment of Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
